INTRODUCTION {#S5}
============

Bariatric surgery is a well-documented treatment option for obesity. In this context, vertical sleeve gastrectomy (VSG), a procedure where the fundus is surgically reduced to create a tubular gastric sleeve, has emerged as a prevalent surgical manipulation ([@R1]). In addition to a significant reduction in appetite and body weight, VSG patients experience improved metabolic profile. Specifically, decreased consumption of palatable/energy dense foods, weight loss, decreased hepatic glucose production and improvement in glucose homeostasis and dyslipidemia have been reported following VSG ([@R2]--[@R4]). One possibility explaining these observations is that VSG reduces appetite by mitigating hedonic hunger to restore metabolic homeostasis.

In the central nervous system, the hypothalamus is a brain region that integrates metabolic signals with internal need to direct behaviors that maintain homeostasis ([@R5]). The hypothalamus contains both orexigenic neuropeptides and anorectic neuropeptides whose release is coordinated to control energy balance and feeding behavior ([@R6]). In this regard, genetic events control the quality of a feeding event whereas physiologic mechanisms initiate or terminate a particular meal. Notably, genetic expression changes within the hypothalamus are sensitive to fluctuations in metabolic status ([@R7]) and feeding behavior ([@R8]). Currently, the behavioral and genetic mechanisms that contribute to reduced appetite and body weight loss after VSG are unresolved.

The current study tested corollaries of the central hypothesis that adaptations in feeding behavior and hypothalamic gene expression contribute to the positive benefits of VSG on body weight loss. Separate from feeding behavior, other bariatric techniques, namely Roux-en-Y Gastric Bypass (RYGB) surgery, stimulates new onset alcohol intake ([@R9]--[@R12]). We recently discovered that RYGB rats increase alcohol intake at the expense of palatable food intake, suggesting that surgery-induced changes in appetite and alcohol intake may be casual ([@R11]). Thus, a separate goal of the current work was to determine if VSG surgery impacted alcohol intake in rats that are otherwise non-preferring prior to surgery. To address these issues, we utilized a rodent model of VSG where male Long Evans rats characterized for body weight loss underwent a battery of behavioral tests designed to assess feeding in the absence of caloric need and new onset alcohol intake. Following behavioral characterization, PCR array analysis was conducted to elucidate alterations in the obesity-related gene expression within the hypothalamus that contributed to VSG-induced behavioral changes.

METHODS {#S6}
=======

Animals {#S7}
-------

Male Long Evans rats (Harlan, IN) housed in an environmentally controlled vivarium on a reverse light cycle (lights off at 7 a.m.) were used with food and water available ad libitum, except when indicated. All procedures were approved by Institutional Animal Care and Use Committee guidelines at Washington State University. Rats (age= \~14 wks) were initially exposed to the high fat diet (HFD; Research Diets, New Brunswick, NJ, 4.41 kcal/g, 1.71 kcal/g from fat) for \~ 8 weeks. Subsequently, rats (n=10/group) received sham or VSG surgery. Out of this, 9 sham and 8 VSG rats completed the study. Following surgery, all rats were maintained on liquid osmolyte and water for the first 5-8 days and were then slowly returned to and maintained on standard rodent chow (Teklad, 3.41 kcal/g, 0.51 kcal/g from fat) throughout the remainder of the study.

Surgery {#S8}
-------

All rats were fasted at-least 24hr before surgery as described previously ([@R11]). On the day of surgery, VSG group of rats were anesthetized and received an incision in the abdominal wall. The stomach was gently removed from the abdominal cavity and lateral stomach (70-80% of total stomach volume) was excised using a stapler (Ethicon, Ithaca, New York), creating a tubular gastric piece connecting esophagus and duodenum. The newly created gastric sleeve was gently placed back, and abdominal cavity was closed. Rats in the sham surgery group were anesthetized, received an incision in the abdominal wall, stomach was gently removed from the cavity and placed back before closing abdominal cavity. All rats received appropriate post-operative care and were allowed to recover until body weight was stable. Subsequently, a subset of rats was tested in hedonic feeding or alcohol drinking paradigms.

Hedonic Food Intake {#S9}
-------------------

To assess hedonic food intake, rats were food deprived overnight as described previously ([@R11], [@R13]). Following 21 hrs, all rats received pre-weighed rodent chow. Food was weighed each hour for 2hrs. Following the second hour of chow access, a preweighed HFD was presented to both Sham and VSG group of rats and food was weighed one hr later. The HFD intake after satisfying homeostatic caloric needs constitutes the hedonic portion of this test.

Alcohol Intake {#S10}
--------------

Unsweetened alcohol (5, 8, or 10% v/v) bottles were presented on alternating days in a counterbalanced fashion in the rat home cages using a two-bottle choice paradigm (one bottle water and another alcohol). Alcohol was introduced 4 hrs into the rat's subjective dark cycle and alcohol and water intake was evaluated 24 hrs later. All animals had ad libitum access to water and food and no water/food deprivation occurred during these testing. The position of alcohol/water bottles were switched at each testing session. Bottles were weighed, gently placed in the cages and re-weighed manually following each session to evaluate alcohol intake (g/kg).

PCR Array {#S11}
---------

Following behavioral assessment, all rats were euthanized, and brain tissues were snap frozen and stored at −80°C until further analysis. Hypothalamus from sham and VSG (n=3/group) was microdissected and placed in RNAlater (Ambion). Tissue Ruptor (QIAGEN, Germantown, MD, USA), QIAshredder (QIAGEN cat\# 79654) and RNeasy Plus mini kit (QIAGEN cat\#74134) were used for total RNA extraction and isolation as described in the manufacturer's protocol. The concentration and purity of RNA samples were determined by Nanodrop spectrophotometer. The degradation and integrity were assessed by Experion Automated Electrophoresis (BioRad, Hercules, CA, USA). All RNA samples were high quality and passed all necessary requirements. cDNA was synthesized from 350ng of total RNA for each sample using RT^2^ First Strand kit (QIAGEN cat\# 330401) following manufacturer's protocol. PCR amplification was conducted using MyiQ Real Time quantitative PCR system (Bio Rad). Baseline threshold was manually set to 100 RFU in primary data analysis for all arrays. The Rat Obesity RT^2^ Profiler PCR arrays (QIAGEN cat\# PARN-017Z) were used to profile expression of a total of 84 genes ([Table 1](#T1){ref-type="table"}), which included orexigenic genes, anorectic genes and genes involved in energy expenditure. All array passed quality control tests (PCR array reproducibility, RT efficiency and genomic DNA contamination). Web based data analysis tool (QIAGEN) was used to calculate fold change and p-values. Two housekeeping genes (*Hprt1* and *Rplp1*) were used for qPCR data normalization. The C~T~ cut-off was set to 35 and any gene with measurements \> 35 were excluded from further analysis. Fold-Change (2\^ (- Delta Delta C~T~)) is the normalized gene expression (2\^ (- Delta Delta C~T~)) in the VSG samples divided by the normalized gene expression (2\^ (- Delta C~T~)) in the sham samples. Fold-regulation represents fold-change results in a biologically meaningful way. Fold-change values greater than one indicates a positive-or an up-regulation, and the fold-regulation is equal to the fold-change. Fold-change values less than one indicate a negative or down-regulation, and the fold-regulation is the negative inverse of the fold-change.

Statistical Analysis {#S12}
--------------------

Body weight, food intake and alcohol intake data over a period of time were analyzed by a mixed-model two-way ANOVA, with post-hoc tests to compare within group effects. The within-subject variable was time interval (time or conditions of measurements) and the between-groups variable was surgical procedure (sham or VSG surgery). HFD intake data were analyzed using unpaired t-test. PCR array data were analyzed using unpaired t-test only as per the manufacturer recommended web-based RT^2^ Profiler PCR Array Data Analysis software and others using this method to evaluate gene expression. All statistical comparisons were conducted at 0.05α level.

RESULTS {#S13}
=======

VSG Surgery: Body Weight {#S14}
------------------------

No statistically significant between group (p\>0.05) differences existed before surgery ([Fig 1A](#F1){ref-type="fig"}). Sham rats lost an average of 10 gm (\~ 2.0 %) of their initial body weight, whereas VSG rats lost an average of 55.0 gm (\~10%) of their initial body weight in the first 30 days following surgery ([Fig 1B](#F1){ref-type="fig"}). A mixed- model ANOVA identified a main effect of time (F~2.5,\ 37.5~ = 52.255, p= 0.000), significant time and treatment interaction (F~2.5,\ 37.5~ = 7.970, p= 0.001) and a significant between group differences (F~1.0,\ 15.0~ = 15.420, p= 0.001) in body weight. In addition, these significant between group differences persisted across time during hedonic feeding (p= 0.0065) and alcohol drinking (p=0.0047) testing ([Fig 1C](#F1){ref-type="fig"}).

VSG Surgery: Hedonic Feeding {#S15}
----------------------------

A mixed model ANOVA identified a significant effect of time (F~2.0,\ 10.0~ = 10.21, p= 0.004), but no significant (p\>0.05) interaction or between groups differences were evident, suggesting that chow intake in both groups decreased over the duration but chow intake was not significantly (p\>0.05) different between sham and VSG group of rats following overnight fasting (a homeostatic driven re-feeding; [Fig 2A](#F2){ref-type="fig"}). However, a palatable food (HFD) intake following a chow pre-load was significantly reduced in the VSG rats compared to the Sham controls ([Fig 2B](#F2){ref-type="fig"}).

VSG Surgery: Alcohol Drinking {#S16}
-----------------------------

Alcohol drinking at lower alcohol (5%) but not higher concentrations (8-10%) appeared to be reduced in the VSG group of rats compared to the Sham controls. However, mixed-model ANOVA did not identify any statistically significant with-in or between-group differences ([Fig 3](#F3){ref-type="fig"}). Water intake was not significantly different between sham and VSG groups.

VSG Surgery: Obesity-related Gene Expression in the Hypothalamus {#S17}
----------------------------------------------------------------

A Rat Obesity RT^2^ Profiler PCR array examined expression of 84 obesity-related genes (i.e., orexigenic, anorectic and energy expenditure) in the hypothalamus following Sham and VSG surgery. Several of these genes were significantly impacted following VSG surgery as shown in the scatter plot ([Fig 4A](#F4){ref-type="fig"}). A total of 71 genes were expressed in detectable amount, whereas 13 genes (*Adipoq, Adra2b, Apoa4, Clps, Gcgr, Gh1, Iapp, Ins1, Lep, Nmur1, Ntrk1, Pparg, Ucp1*) were deemed undetectable (based on C~T~ values). [Table 2](#T2){ref-type="table"} summarizes the list of these 71 genes and their corresponding PCR array data. Of these 71 genes, 8 genes (*Adipor1, Agrp, Cartpt, Glp1r, HcRt, llb, Lepr, Mc3r*) were significantly (p\<0.05) downregulated and one gene (*Grp*) was significantly (p\<0.05) upregulated in the hypothalamus of VSG rats compared to sham controls. Furthermore, ≥ 2-fold statistical increase and decrease were evident in *Agrp, Cartpt, Glp1r, HcRt, llb, Lepr, Mc3r* and *Grp*, respectively ([Fig 4B](#F4){ref-type="fig"}).

DISCUSSION {#S18}
==========

The present study was designed to test corollaries of the central hypothesis that VSG surgery selectively attenuates palatable food intake through modulation of genetic information flow within the hypothalamus. From these efforts, we discovered that VSG surgery in male rodents led to anticipated reductions in body weight that was sustained throughout the study period. In addition, VSG surgery attenuated palatable food intake following a caloric preload, but spared deprivation-induced re-feeding behavior. This observation supports the contention that VSG is not a restrictive surgery but rather limits excess intake in the absence of a caloric need. Although, alcohol drinking was moderately impacted at lower alcohol concentration, this effect diminished as the concentration of alcohol was escalated. Behaviorally characterized VSG rats displayed decreased expression of key *orexigenic* hypothalamic transcripts linked to stimulation of both food and alcohol intake. Collectively, these results suggest that weight loss after surgical reconstruction of the stomach in VSG is accompanied by behavioral and neurobiological events that signify reduced drive for palatable food.

Roux-en-Y Gastric Bypass (RYGB) surgery and Vertical Sleeve Gastrectomy (VSG) are the most widely performed surgical procedures to induce sustained weight loss for the treatment of obesity and related metabolic complications ([@R1]). VSG has emerged as a popular and frequently performed surgical procedure for obesity treatment given its efficiency (several metabolic benefits even at \~ 20% mean reduction in the body weight) and allowance of revisional procedures ([@R1]). Furthermore, a significant reduction in the fat and fat-free mass has been reported following VSG ([@R14]). However, large variability exists in body weight reduction following VSG ([@R15]) and both preclinical and clinical studies report body weight regain following bariatric procedures, including VSG ([@R16]--[@R18]). It is important to note that marked variability in the maximal weight loss following bariatric surgeries could be attributed to several factors, including age at which the surgical procedure is performed, pre-operative BMI, % early weight loss following surgery, poor-diet quality, incompliance with post-operative dietary recommendations, emotional eating, increase food craving and/or pre-operative food preferences ([@R17]--[@R22]).

In this context, hedonic feeding (consumption of a palatable food in the absence of a caloric need) could be a major contributor to the individual difference in weight regain after VSG. Notably, preclinical evidence indicates that preoperative food preference for palatable food is maintained after VSG ([@R18], [@R23]), highlighting perseverance for unhealthy food as a means to stimulate body weight regain. However, it is unknown if palatable food intake is impacted in the absence of caloric needs following VSG. The data we present here indicate for the first time that VSG rats selectively reduced intake of palatable food, when offered a high fat diet after consuming a caloric pre-load. Supporting this finding, preclinical studies indicate that VSG rats decrease preference for high fat foods despite displaying persistence of food-motivated behavior ([@R24]). Importantly re-feeding on low fat food after deprivation did not differ between VSG rats and sham controls, suggesting that VSG is not a restrictive surgical procedure. Instead, relative to controls, VSG rats selectively reduced intake when offered a palatable high fat diet after consuming a caloric pre-load. Consistent with this, clinical evidence indicates that VSG reduces preference and liking for high caloric foods (rich in fat and sugar) ([@R3], [@R25]). Taken together, these results suggest that VSG selectively abrogates hedonic feeding in the absence of a caloric need.

Previous work from our group and others indicate that RYGB surgery increases alcohol intake in rodents. Specifically, RYGB surgery increases sensitivity, consumption and motivation to obtain alcohol ([@R9]--[@R11]) in rats that are non-alcohol preferring at baseline. Moreover, we recently discovered that this phenomenon occurs at the expense of reduced hedonic feeding ([@R11]). That is, RYGB rats that displayed increased alcohol intake also selectively reduced hedonic intake of palatable food after a caloric pre-load. To determine if surgical effects on alcohol extend to the VSG procedure, we examined alcohol intake over a range of alcohol concentrations. Our data indicate that VSG reduced intake of alcohol at low concentration and that this phenomenon is diminished as the concentration of alcohol is escalated. These data are in agreement with a recent preclinical study that found reduced alcohol intake after VSG surgery ([@R26]). However, in that study, VSG rats and mice consumed significantly less alcohol at all concentrations tested. It is important to note that VSG rats were directly compared to non-surgical controls in that study. Whereas in the current study, sham rats that served as controls experienced the same degree of perioperative stress but did not undergo surgical reduction of the fundus. Thus, these differences in alcohol consumption among control groups may have contributed to the disparity in results between the two studies. In either case, we conclude that if anything, VSG reduces alcohol intake as opposed to RYGB, which stimulates new onset alcohol intake in both patients ([@R12]) and rodents ([@R9], [@R10]).

It is important to note that anatomical and resultant physiological alterations following surgeries that re-structure the gastrointestinal tract can impact alcohol pharmacokinetics. For example, rapid absorption, higher blood alcohol concentration and delayed alcohol elimination have been reported following RYGB, which may contribute to the development of AUD in these patients, nicely reviewed elsewhere ([@R27]). On the other hand, fewer studies have examined alcohol pharmacokinetics and alcohol intoxication following VSG and have generated conflicting results. For example, a prospective study (n=10) compared alcohol metabolism, peak blood alcohol concentration, alcohol elimination and intoxication before and after (3 and 12 months) VSG and found no significant changes ([@R28]). Similar results were obtained by an additional study that examined the impact of VSG (n=7) and gastric banding (n=9) on alcohol pharmacokinetics and intoxication following 3- and 6-months of surgery ([@R29]). These data are consistent with our preclinical finding demonstrating no change in alcohol drinking following VSG. In contrast, Maluenda et al. (2010) reported increased blood alcohol levels and delayed alcohol clearance 2 months following VSG in 12 patients ([@R30]). Therefore, additional well-controlled clinical studies are needed to assess alcohol pharmacokinetics and the risk of development of AUD following VSG.

Interestingly, males and females exhibit similar rates of obesity. Although, the number of male patients seeking bariatric procedures continues to grow, females constitute the majority of patients undergoing these surgeries. Since the current study examined the impact of VSG on hedonic feeding and alcohol drinking in male rats only, future studies are needed to determine if similar effects persist in females. In this context, a clinical study reported no significant changes in the alcohol pharmacokinetics (examined using Breathalyzer) and intoxication levels 3- and 12-months following VSG, primarily in females ([@R28]). However, a recent study argued that the Breathalyzer method may be unreliable and that more robust analytical methods (e.g., gas chromatography) are needed to assess alcohol pharmacokinetics following bariatric surgery ([@R31]). For example, Acevedo et al found faster absorption, higher peak blood alcohol levels and heightened intoxications in 11 women \~2.0 years following VSG using this method ([@R31]). Interestingly, a very recent, large, multi-institutional study based on self-reported alcohol consumption found similar pre- and post-operative (1 and 2 yr) AUD prevalence following RYGB (n=1006, 78.4% female) and VSG (n=4718, 78.4% female). In this study, AUD was detected 2-yrs following RYGB or VSG. Notably income, education, baseline alcohol consumption or alcohol misuse were predictive for AUD after surgery ([@R32]). Collectively, these data highlight the importance of method, time following surgery and history of alcohol misuse as critical factors that should be considered when evaluating the impact of VSG on new onset of AUD.

The hypothalamus integrates metabolic information with internal need to adapt behavioral responses. Specifically gastrointestinal (GI) derived peptides target the hypothalamus to regulate energy balance through modulation of feeding behavior ([@R5]). To examine potential mechanisms for the observed reduced hedonic feeding, we measured mRNA changes in the hypothalamus of VSG rats that were behaviorally characterized for reduced hedonic feeding and low concentration alcohol intake. Our results indicate that VSG dramatically reduced expression of key *orexigenic* peptides known to stimulate food intake. For example, Agouti related peptide (AgRP) is a neuropeptide with well-established effects on appetite stimulation ([@R33]). Activation of AgRP neurons drives feeding in untrained rodents ([@R34]), demonstrating that these neurons are necessary and sufficient to initiate feeding. We find that AgRP mRNA is significantly decreased after VSG relative to sham control rats. Pharmacologic AgRP selectively drives preferences for fat and stimulates mesocortical dopamine release ([@R35]). Thus, reduced hedonic feeding in VSG may derive from reduced AgRP expression. We also detected decreased HcRt or orexin mRNA in the hypothalamus of VSG rats. Notably, orexin signaling is required for hedonic feeding behavior in rodents ([@R36]). In addition, orexin promotes alcohol intake in rodents ([@R37]). Thus, decreased orexin expression may also contribute to the reduction in hedonic feeding and/or low concentration alcohol intake observed after VSG surgery. We also detected decreased expression (a strong trend p=0.05) of ghrelin receptor-1a (GHSR), the central target of the appetite hormone ghrelin ([@R38]). In addition to promoting appetite, ghrelin also stimulates alcohol intake ([@R39]). Notably, VSG reduces circulating ghrelin in humans ([@R40]) and rodents ([@R41]) indicating that hypothalamic reduction in GHSR mRNA expression may derive from reduced circulating ghrelin. In support of this contention, we recently discovered that RYGB rats with reduced circulating ghrelin have diminished GHSR control of dopamine neuronal firing ([@R11]), suggesting that reduced plasma ghrelin may lead to reductions in central GHSR function. A significant decrease in leptin receptor mRNA expression was also observed in the hypothalamus of VSG rats. Notably, studies have reported decreased circulating leptin hormone following VSG ([@R42]). It is important to note that leptin concentration and sensitivity closely correlate with the body weight as obesity increases whereas weight loss decreases plasma leptin levels ([@R43]). Therefore, a decreased leptin receptor expression in the present study could be a consequence of reduced body weight following VSG surgery. Interestingly, leptin positively regulates hypothalamic CART (cocaine- and amphetamine-regulated transcript) mRNA levels ([@R44]). We observed a significant decrease in the CART prepropeptide mRNA expression in the hypothalamus of VSG rats, which is in agreement with the decreased leptin functional activity following VSG. Notably, we also discovered that VSG led to up-regulation of gastrin releasing peptide (GRP) a peptide produced in the gastrointestinal tract and hypothalamus that inhibits food intake ([@R45]). Collectively, these results indicate that VSG surgery exerts dramatic alterations in the genetic expression in the brain's endogenous appetite center that potentially contributes to reduced drive to feed. It is important to note whether similar changes could be attributed to the weight loss itself, independent of surgery, is unclear which requires further investigation.

To summarize, the current data indicate that VSG surgery may exert positive benefits on body weight loss through reductions in hedonic intake of palatable food, an effect that occurs without risk of new onset alcohol misuse and potentially explained by alterations in genetic information flow within the hypothalamus. These data can inform development of new therapies designed to reduce body weight with reduced risk of developing alcohol use disorder.
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![VSG surgery promoted moderate but sustained decreases in body weight.\
**A)** There were no significant differences in the baseline pre-surgery body weight between sham and VSG rats. **B)** VSG surgery led to a moderate but significant (p= 0.001) decrease in body weight relative to sham controls. \*\*p\<0.01 main effect of VSG Surgery. **C)** Significant (p\<0.01) body weight differences existed between sham and VSG groups at each behavioral testing interval after surgery.](nihms-1515916-f0001){#F1}

![VSG Surgery Selectively Attenuated Hedonic Feeding.\
**A)** No significant between group differences in chow intake were observed when rat received chow following an overnight deprivation. \*\*p\<0.01 main effect of time. **B)** In contrast, when HFD was presented during 3^rd^ hr, after re-feeding had ceased, VSG rats displayed a significant reduction in HFD intake (p= 0.029) compared to the sham controls. \*p\<0.05 compared to sham controls.](nihms-1515916-f0002){#F2}

![VSG surgery did not impact alcohol drinking.\
Data represent mean (±sem) alcohol (5.0-10.0% v/v) consumption (g/kg). When tested around 45 days following VSG surgery, alcohol drinking levels did not differ between groups.](nihms-1515916-f0003){#F3}

![Alterations in the hypothalamic obesity-related gene expression following VSG surgery in rats.\
**A)** Scatter plot analysis of differential expression of obesity-related genes in the hypothalamus following VSG compared to the sham controls, using the Rat Obesity RT^2^ Profiler PCR Array. Each dot represents one gene and the top and bottom genes outside the dotted lines represent 2-fold increase and decrease, respectively. **B)** Fold regulation (≥ 2-fold) is plotted for only statistically significant (p\<0.05) increased or decreased gene expression following VSG compared to the sham controls. \*\*p\<0.01 and \*p\<0.05 compared to sham controls.](nihms-1515916-f0004){#F4}

###### 

A Panel of Gene Examined Using a Rat RT^2^ Profiler PCR Array

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **[OREXIGENIC GENES]{.ul}**
  **Neuropeptides & Receptors**: *Adra2b, Agrp, Cnr1, Gal, Galr1, Mchr1, Hcrt, Hcrtr1, Npy, Npy1r, Nr3c1 (Grl), Oprk1, Oprm1, Sigmar1 (Oprs1).*
  **Gut Hormones & Receptors**: *Ghrl (Ghrelin, Obestatin), Ghsr.*
  **[ANORECTIC GENES]{.ul}**
  **Neuropeptides & Receptors**: *Atrn, Bdnf, Brs3, Calca, Calcr, Cartpt, Cntf, Cntfr, Crh, Crhr1, Drd1, Drd2, Gh1, Ghr, Prlhr (Gpr10), Grp, Grpr, Hrh1, Htr2c, Il1a, Il1b, Il1r1, Il6, Il6r, Mc3r, Nmb, Nmbr, Nmu, Nmur1 (Gpr66), Ntrk1, Nts, Ntsr1, Pomc, Sort1, Trh, Trhr, Ucn.*
  **Gut Hormones & Receptors**: *Apoa4, Cck, Cckar, Glp1r, Pyy.*
  **Adipocyte-Derived Peptides & Receptors**: *Lep (Leptin), Lepr, Tnf.*
  **Pancreas Derived Peptides & Receptors**: *Calcr, Clps, Gcg, Gcgr, Glp1r, Iapp, Ins1, Ins2, Insr, Ramp3, Sst, Sstr1.*
  **[ENERGY EXPENDITURE]{.ul}**
  **Adipocyte-Derived Peptides & Receptors**: *Adipoq (Acrp30), Adipor1, Adipor2, Adrb1, C3, Ppara, Pparg, Ppargc1a (Ppargc1), Ptpn1 (Ptp), Ucp1.*
  **CNS-Derived Peptides & Receptors**: *Adcyap1, Adcyap1r1, Thrb.*
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Impact of Vertical Sleeve Gastrectomy on Obesity-Related Gene Expression in Hypothalamus Using the Rat Obesity RT^2^ Profiler PCR Array.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#         Unigene           Refseq               Symbol          Description                                                             Fold\         p value
                                                                                                                                            Regulation    
  ---------- ----------------- -------------------- --------------- ----------------------------------------------------------------------- ------------- -----------------------------------------------
  1          Rn.202559         NM_016989            Adcyap1         Adenylate cyclase activating polypeptide 1                              −2.0          0.192

  2          Rn.234543         NM_133511            Adcyap1r1       Adenylate cyclase activating polypeptide 1 receptor 1                   −1.4          0.174

  ***3***    ***Rn.104556***   ***NM_207587***      ***Adipor1***   ***Adiponectin receptor 1***                                            ***−1.3***    ***0.021***[\*](#TFN3){ref-type="table-fn"}

  4          Rn.101984         NM_001037979         Adipor2         Adiponectin receptor 2                                                  −1.2          0.122

  5          Rn.87064          NM_012701            Adrb1           Adrenergic, beta-1-, receptor                                           −1.2          0.715

  ***6***    ***Rn.137597***   ***NM_033650***      ***Agrp***      ***Agouti related protein homolog (mouse)***                            ***−27.1***   ***0.024***[\*](#TFN3){ref-type="table-fn"}

  7          Rn.53846          NM_031351            Atrn            Attractin                                                               −1.4          0.226

  8          Rn.11266          NM_012513            Bdnf            Brain-derived neurotrophic factor                                       −1.9          0.230

  9          Rn.86415          NM_152845            Brs3            Bombesin-like receptor 3                                                −2.1          0.127

  10         Rn.11378          NM_016994            C3              Complement component 3                                                  −4.5          0.300

  11         Rn.90085          NM_017338            Calca           Calcitonin-related polypeptide alpha                                    −1.6          0.188

  12         Rn.10062          NM_053816            Calcr           Calcitonin receptor                                                     −1.0          0.928

  ***13***   ***Rn.89164***    ***NM_017110***      ***Cartpt***    ***CART prepropeptide***                                                ***−3.0***    ***0.004***[\*\*](#TFN2){ref-type="table-fn"}

  14         Rn.9781           NM_012829            Cck             Cholecystokinin                                                         −1.7          0.547

  15         Rn.10184          NM_012688            Cckar           Cholecystokinin A receptor                                              −1.3          0.145

  16         Rn.89774          NM_012784            Cnr1            Cannabinoid receptor 1 (brain)                                          1.4           0.408

  17         Rn.6067           NM_013166            Cntf            Ciliary neurotrophic factor                                             −1.1          0.603

  18         Rn.55036          NM_001003929         Cntfr           Ciliary neurotrophic factor receptor                                    −1.1          0.595

  19         Rn.10349          NM_031019            Crh             Corticotropin releasing hormone                                         2.2           0.100

  20         Rn.10499          NM_030999            Crhr1           Corticotropin releasing hormone receptor 1                              −1.0          0.905

  21         Rn.24039          NM_012546            Drd1            Dopamine receptor D1A                                                   2.2           0.286

  22         Rn.87299          NM_012547            Drd2            Dopamine receptor D2                                                    1.1           0.826

  23         Rn.8929           NM_033237            Gal             Galanin prepropeptide                                                   −1.4          0.234

  24         Rn.10213          NM_012958            Galr1           Galanin receptor 1                                                      1.0           0.955

  25         Rn.54383          NM_012707            Gcg             Glucagon                                                                −1.2          0.490

  26         Rn.2178           NM_017094            Ghr             Growth hormone receptor                                                 −1.2          0.628

  27         Rn.42103          NM_021669            Ghrl            Ghrelin/obestatin prepropeptide                                         −1.2          0.544

  28         Rn.74241          NM_032075            Ghsr            Growth hormone secretagogue receptor                                    −2.3          0.054

  ***29***   ***Rn.11408***    ***NM_012728***      ***Glp1r***     ***Glucagon-like peptide 1 receptor***                                  ***−2.1***    ***0.023***[\*](#TFN3){ref-type="table-fn"}

  ***30***   ***Rn.10930***    ***NM_133570***      ***Grp***       ***Gastrin releasing peptide***                                         ***4.6***     ***0.006***[\*\*](#TFN2){ref-type="table-fn"}

  31         Rn.10316          NM_012706            Grpr            Gastrin releasing peptide receptor                                      −1.0          0.860

  ***32***   ***Rn.7628***     ***NM_013179***      ***HcRt***      ***Hypocretin***                                                        ***−10.5***   ***0.039***[\*](#TFN3){ref-type="table-fn"}

  33         Rn.88262          NM_013064            Hcrtr1          Hypocretin (orexin) receptor 1                                          −1.5          0.191

  34         Rn.81032          NM_017018            Hrh1            Histamine receptor H 1                                                  −1.8          0.149

  35         Rn.9935           NM_012765            Htr2c           5-hydroxytryptamine (serotonin) receptor 2C                             1.0           0.800

  36         Rn.12300          NM_017019            Il1a            Interleukin 1 alpha                                                     1.1           0.512

  ***37***   ***Rn.9869***     ***NM_031512***      ***Il1b***      ***Interleukin 1 beta***                                                ***−2.9***    ***0.016***[\*](#TFN3){ref-type="table-fn"}

  38         Rn.9758           NM_013123            Il1r1           Interleukin 1 receptor, type I                                          −1.2          0.341

  39         Rn.9873           NM_012589            Il6             Interleukin 6                                                           −1.1          0.457

  40         Rn.1716           NM_017020            Il6r            Interleukin 6 receptor                                                  −1.2          0.435

  41         Rn.989            NM_019130            Ins2            Insulin 2                                                               −1.7          0.193

  42         Rn.9876           NM_017071            Insr            Insulin receptor                                                        −1.1          0.436

  ***43***   ***Rn.9891***     ***NM_012596***      ***Lepr***      ***Leptin receptor***                                                   ***−2.4***    ***0.014***[\*](#TFN3){ref-type="table-fn"}

  ***44***   ***Rn.215838***   ***NM_001025270***   ***Mc3r***      ***Melanocortin 3 receptor***                                           ***−2.3***    ***0.023***[\*](#TFN3){ref-type="table-fn"}

  45         Rn.10822          NM_031758            Mchr1           Melanin-concentrating hormone receptor 1                                1.1           0.120

  46         Rn.18763          NM_001109149         Nmb             Neuromedin B                                                            1.1           0.715

  47         Rn.89709          NM_012799            Nmbr            Neuromedin B receptor                                                   2.4           0.064

  48         Rn.47720          NM_022239            Nmu             Neuromedin U                                                            −5.0          0.076

  49         Rn.9714           NM_012614            Npy             Neuropeptide Y                                                          −1.4          0.088

  50         Rn.11642          NM_001113357         Npy1r           Neuropeptide Y receptor Y1                                              −1.0          0.984

  51         Rn.90070          NM_012576            Nr3c1           Nuclear receptor subfamily 3, group C, member 1                         −1.3          0.082

  52         Rn.60814          NM_001102381         Nts             Neurotensin                                                             3.2           0.089

  53         Rn.200149         NM_001108967         Ntsr1           Neurotensin receptor 1                                                  −1.1          0.708

  54         Rn.89571          NM_017167            Oprk1           Opioid receptor, kappa 1                                                1.2           0.206

  55         Rn.10118          NM_013071            Oprm1           Opioid receptor, mu 1                                                   1.3           0.255

  56         Rn.108195         NM_139326            Pomc            Proopiomelanocortin                                                     −10.3         0.327

  57         Rn.9753           NM_013196            Ppara           Peroxisome proliferator activated receptor alpha                        −1.1          0.584

  58         Rn.19172          NM_031347            Ppargc1a        Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha   1.2           0.396

  59         Rn.138127         NM_139193            Prlhr           Prolactin releasing hormone receptor                                    1.8           0.137

  60         Rn.11317          NM_012637            Ptpn1           Protein tyrosine phosphatase, nonreceptor type 1                        −1.1          0.834

  61         Rn.13173          NM_001034080         Pyy             Peptide YY (mapped)                                                     −1.9          0.143

  62         Rn.48672          NM_020100            Ramp3           Receptor (G protein-coupled) activity modifying protein 3               −1.4          0.147

  63         Rn.1129           NM_030996            Sigmar1         Sigma non-opioid intracellular receptor 1                               1.1           0.455

  64         Rn.11286          NM_031767            Sort1           Sortilin 1                                                              −1.1          0.543

  65         Rn.34418          NM_012659            Sst             Somatostatin                                                            2.1           0.138

  66         Rn.42915          NM_012719            Sstr1           Somatostatin receptor 1                                                 −1.0          0.975

  67         Rn.34019          NM_012672            Thrb            Thyroid hormone receptor beta                                           −1.6          0.101

  68         Rn.2275           NM_012675            Tnf             Tumor necrosis factor (TNF superfamily, member 2)                       −1.1          0.442

  69         Rn.22             NM_013046            Trh             Thyrotropin releasing hormone                                           1.7           0.241

  70         Rn.9962           NM_013047            Trhr            Thyrotropin releasing hormone receptor                                  1.2           0.368

  71         Rn.10190          NM_019150            Ucn             Urocortin                                                               −2.1          0.156
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bold text highlights statistically significant changes.

p\<0.01 and

p\<0.05 compared to sham controls.

-   Roux-en-Y gastric bypass (RYGB) surgery and Vertical Sleeve Gastrectomy (VSG) are the most effective and commonly performed bariatric procedures for sustained body weight loss.

-   Both preclinical and clinical studies report new onset alcohol misuse following RYGB surgery.

-   The impact of VSG on alcohol intake is less clear.
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-   VSG induced a moderate but significant and sustained weight loss in rats.

-   VSG attenuated hedonic feeding without impacting alcohol drinking, an effect potentially mediated by alterations in genetic information flow within the hypothalamus.

-   Importantly, these data highlight VSG as an effective bariatric procedure with potentially reduced risk of developing alcohol use disorder.
